Genovis AB Stock Nasdaq Stockholm
Equities
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
||
- SEK | - |
Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Feb. 15 | Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2024 * | 137M 12.82M | Sales 2025 * | 235M 21.97M | Capitalization | 2.26B 211M |
---|---|---|---|---|---|
Net income 2024 * | 31M 2.89M | Net income 2025 * | 40M 3.73M | EV / Sales 2024 * | 15.7 x |
Net cash position 2024 * | 109M 10.2M | Net cash position 2025 * | 105M 9.83M | EV / Sales 2025 * | 9.15 x |
P/E ratio 2024 * |
71.9
x | P/E ratio 2025 * |
19.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.42% |
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 20-05-04 | |
Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
1st Jan change | Capi. | |
---|---|---|
-4.57% | 12.32B | |
-4.35% | 8.1B | |
+8.91% | 5.87B | |
+30.81% | 5.52B | |
-7.42% | 4.29B | |
-54.27% | 3.16B | |
+14.44% | 2.72B | |
-2.21% | 2.37B | |
+28.53% | 2.23B |